Loading…
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Legislative Progress
Introduced
November 18, 2021
Latest Action
November 18, 2021
Primary Sponsor
Jeanne ShaheenDemocratic(NH)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
This bill increases the number of days—from 14 to 60—within which a practitioner must administer certain narcotic drugs (e.g., buprenorphine) to a patient for maintenance or detoxification treatment (i.e., substance use disorder treatment) after receiving the drugs from a pharmacy. Additionally, the bill revises the process by which the Department of Justice may modify the number of days within which such drugs must be administered.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2022 · fourth_quarter · Health Issues
HR 5950 and S 3257, the Improving Patient Access to Care and Treatment Act. Reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Read twice and referred to the Committee on the Judiciary.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $5,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R.1475/S.1795, Pursuing Equity in Mental Health Act H.R.2955/S.4448, Suicide Prevention Act H.R.3259/S.586, NOPAIN Act H.R.3467/S.4332, Improving Data Collection for Adverse Childhood Experiences Act H.R.4040, Advancing Telehealth Beyond COVID-19 Act H.R.5611/S.1902 Behavioral Health Crisis Services Expansion Act H.R. 6302, The Protecting the Health of Americas Older Adults Act H.R.7116, 9-8-8 Implementation Act of 2022 H.R.7666, Restoring Hope for Mental Health and Well-Being Act of 2022 H.R. 7780 Mental Health Matters Act H.R.8800, Supporting Medicare Providers Act of 2022 S. 5272 / H.R. 9577, Increasing Mental Health Options Act S.2086, RISE from Trauma Act S.2425, Suicide Prevention Lifeline Improvement Act of 2021 S. 3257 A bill to lengthen the period of time during which certain controlled substances must be administered S.4170, Mental Health Reform Reauthorization Act S.4301, Substance Use Prevention, Treatment, and Recovery Act S.4306, Improving Access to Behavioral Health Integration Act S.4472, Health Care Capacity for Pediatric Mental Health Act S.4616, Behavioral Health Coverage Transparency Act of 2022 S.4804, Parity Enforcement Act of 2022 S. 5310 Helping Kids Through Trauma Act H.R. 7644, Pride in Mental Health Act S. 4747, Invest in Kids' Mental Health Now Act H.R. 5218, Collaborate in an Orderly and Cohesive Manner Act S. 4306, Improving Access to Behavioral Health Integration Act H.R.8391, the CONtinuity in Necessary Evaluative Crisis Treatment (CONNECT) Act H.R. 9109, GRIEF Act H.R. 2617, Consolidated Appropriations Act, 2023 Discussion of population health-based approaches - Rep. Smith (WA) General population health and rural mental health access solutions Grass-tops summit on year-end mental health package Response to RFI re: No Surprises Act Response to RFI re: provider directory
Client expense: $480,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R.1475/S.1795, Pursuing Equity in Mental Health Act H.R.2955/S.4448, Suicide Prevention Act H.R.3259/S.586, NOPAIN Act H.R.3467/S.4332, Improving Data Collection for Adverse Childhood Experiences Act H.R.4040, Advancing Telehealth Beyond COVID-19 Act H.R.5611/S.1902 Behavioral Health Crisis Services Expansion Act H.R. 6302, The Protecting the Health of Americas Older Adults Act H.R.7116, 9-8-8 Implementation Act of 2022 H.R.7666, Restoring Hope for Mental Health and Well-Being Act of 2022 H.R. 7780 Mental Health Matters Act H.R.8800, Supporting Medicare Providers Act of 2022 S. 5272 / H.R. 9577, Increasing Mental Health Options Act S.2086, RISE from Trauma Act S.2425, Suicide Prevention Lifeline Improvement Act of 2021 S. 3257 A bill to lengthen the period of time during which certain controlled substances must be administered S.4170, Mental Health Reform Reauthorization Act S.4301, Substance Use Prevention, Treatment, and Recovery Act S.4306, Improving Access to Behavioral Health Integration Act S.4472, Health Care Capacity for Pediatric Mental Health Act S.4616, Behavioral Health Coverage Transparency Act of 2022 S.4804, Parity Enforcement Act of 2022 S. 5310 Helping Kids Through Trauma Act H.R. 7644, Pride in Mental Health Act S. 4747, Invest in Kids' Mental Health Now Act H.R. 5218, Collaborate in an Orderly and Cohesive Manner Act S. 4306, Improving Access to Behavioral Health Integration Act H.R.8391, the CONtinuity in Necessary Evaluative Crisis Treatment (CONNECT) Act H.R. 9109, GRIEF Act H.R. 2617, Consolidated Appropriations Act, 2023 Discussion of population health-based approaches - Rep. Smith (WA) General population health and rural mental health access solutions Grass-tops summit on year-end mental health package Response to RFI re: No Surprises Act Response to RFI re: provider directory
Client expense: $480,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
HR 5950 and S 3257, the Improving Patient Access to Care and Treatment Act. Reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: Not reported · Firm income: Not reported
2021 · fourth_quarter · Insurance
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Alcohol and Drug Abuse
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Pharmacy
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Health Issues
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Medicare/Medicaid
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Alcohol and Drug Abuse
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Insurance
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Medicare/Medicaid
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Health Issues
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Pharmacy
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office